AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06003855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy
Description: Subjects will be enrolled in a 12-week intervention program of either modified supervised exercise therapy or standard supervised exercise therapy. The program will be 3 sessions/week for 12 weeks. Each session will consist of 50 minutes plus 5 minutes warm up and cool down.
Study NCT06003855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise therapy
Description: Subjects will be enrolled in a 12-week intervention program of either modified supervised exercise therapy or standard supervised exercise therapy. The program will be 3 sessions/week for 12 weeks. Each session will consist of 50 minutes plus 5 minutes warm up and cool down.
Study NCT05007483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BodyBio Balance Oil
Description: nutraceutical supplement
Study NCT05007483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kirunal Fish Oil
Description: nutraceutical supplement
Study NCT05007483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BodyBio PC
Description: nutraceutical supplement
Study NCT06539208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YOLT-201
Description: Infusion of YOLT-201 at Day 1
Study NCT05266053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO 7 dressing
Description: The PICO 7 dressing consists of a negative pressure wound therapy pump (NPWT) connected to an absorbent gentle adhesive dressing that is applied to a wound. When the pump is activated, it acts by pulling excess fluid from the wound. The dressing absorbs this fluid and helps to prevent bacteria from entering the wound. It has been shown to prevent wound infections and promote healing.
Study NCT05266053 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard wound dressing
Description: Standard abdominal dressing at the time of cesarean
Study NCT06582576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Effect of different gastric electrical stimulator stimulation paragdimes on brain, heart, and stomach.
Description: Measuring EEG, ECG, and ultrasound in both groups during different stimulation intensities provided by the previously implanted gastric electrical stimulator.
Study NCT05007483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Paleolithic Elimination diet
Description: 1. Complete elimination of all gluten-, dairy-, and egg-containing foods.~2. Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.~3. Consume 6-12 ounces/day protein including organ meats and fatty fish.~4. Consume fermented foods daily.~5. Consume daily servings of algae, seaweed, and nutritional yeast.
Study NCT05007483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Olive Oil Based (TROO) Ketogenic Diet
Description: 1. Restriction of dietary carbohydrates to \< 50 grams/day.~2. Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to >160 grams/day.~3. Consume \<100 grams/day protein.~4. Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).~5. Consume at least 3 servings/day non-starchy vegetables.
Study NCT05007483 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet with Dietary Guidelines for Americans Diet information
Description: 1. Limit sodium to \< 2,300 mg/day.~2. Limit added sugar and saturated fat intake to \<10% of kcal/day, respectively.~3. Consume 5 servings of fruits and vegetables per day.~4. Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.~5. Consume 3 servings of reduced fat dairy per day.~6. Consume 6 ounces/day protein foods.
Study NCT06126549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Building Better Caregivers
Description: Peer-led, group intervention for caregivers focused on problem-solving
Study NCT06126549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Training
Description: Clinician-led, one-to-one intervention for caregivers focused on problem-solving
Study NCT06126549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual discharge training and support offered to family caregivers of ABI patients
Study NCT06333938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridge
Description: Percutaneous Nerve Field Stimulation using a disposable battery operated and device, approved by the FDA for the treatment of clinical symptoms related to opioid withdrawal.
Study NCT06333938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BFA
Description: BFA is an auricular acupuncture technique (developed within the VA/ DoD health systems) delivered by providers using 1mm acupuncture needles.
Study NCT06196970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilate exercises
Description: After 10 minutes of warmup excercises, participatants perform pilates exercises, Pelvic curl : 45 seconds hold The Hundred : 45 seconds hold Bird Dog : 45 seconds hold Side plank : 45 seconds hold Frequency 3 days a week intensity 45 minutes hold a pose. Time will be 10 to 15 minutes.
Study NCT06196970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burpees exercises
Description: After 10 minutes of warmup excercises, participatants perform burppes excercises.~1. Stand straight with your feet shoulder-width apart.~2. Squat and place your hands in front of your feet.~3. Jump back until your legs are fully extended and your body is in plank position.~4. Do a push up, jump forward, and then push through the heels to return to the starting position.~5. Repeat until the set is complete. Frequency 3 days a week .Time 10 to 15 minutes with 10 reputation , 3 sets. Rest internal will be 10 seconds after each set.
Study NCT04793152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Administration as outlined
Study NCT04793152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Administration as outlined
Study NCT04974593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low fat diet
Description: A trained dietitian will provide instruction of the LFD according to standard practice.
Study NCT05198349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1069
Description: Participants received escalated oral dose of M1069, twice daily (BID) until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from study intervention.
Study NCT06076538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging
Description: PET/MR scan utilizing FDG Radiopharmaceutical
Study NCT05159713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCBI
Description: The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation.
Study NCT05159713 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
Study NCT05159713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
Study NCT06648499 — intervention group
Intervention type: OTHER
Intervention: Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in POMS
Description: The demographic information of the patients will be taken with the form prepared for the people in this group. Patients will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
Study NCT06041477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU
Description: Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks)
Study NCT06041477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU
Description: Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks)
Study NCT06041477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Lenvatinib
Description: Lenvatinib 8mg/day combined with the HAIC from the first cycle
Study NCT06041477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent PD-1 antibody
Description: PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the first cycle (dosage and frequency according to instructions)
Study NCT06041477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential Lenvatinib
Description: Lenvatinib 8mg/day combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR)
Study NCT05759143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nest Platform
Description: Patient- and clinician-facing portal via secure link
Study NCT06648499 — intervention group
Intervention type: OTHER
Intervention: Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in healthy controls
Description: The demographic information of the healthy controls will be taken. Healthy controls will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
Study NCT05784311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Description: 1500mg IV cefuroxime thrice daily during five days.
Study NCT05784311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 500mg IV metronidazole thrice daily during five days.
Study NCT05228990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: warm acupunctrue
Description: The sterile acupuncture needle (0.3mm×40mm) is taken, and the acupuncture needle is vertically inserted into the corresponding depth of the acupoint. After the needle is transported to get qi, moxibustion will be added at acupoints. The moxibustion distance is about 3cm from the skin, and the local temperature is warm and the patient felt comfortable with the skin. Replace it after burning out. During the acupuncture treatment, in order to avoid burns, it is necessary to strictly control the distance between moxibustion and skin. In the supine position, cardboard should be placed between moxibustion and skin to prevent burns, and ashes should be removed after moxibustion is completely burned. The needle is left for 20 minutes.
Study NCT06014008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product consumption group
Description: Participants will take one bottle (80 ml) of Yakult® drink daily for a period of 4 weeks. Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota. Subsequently, a two-week follow-up period will follow.
Study NCT05675930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy
Description: Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the treatment arm will be treated with oral photobiomodulation/PBM (via Thor LX2.3 system device) for 28 days
Study NCT05675930 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sham device
Description: Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the placebo arm will be treated with a placebo sham device (via Thor LX2.3 sham device setting) for 28 days
Study NCT05667012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational videos
Description: There will be a total of 6 videos, each of these videos will last between 8 and 10 minutes and will be accessed through a YouTube link to a private channel.
Study NCT05667012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational videos
Description: There will be a total of 6 videos, each of these videos will last between 8 and 10 minutes and will be accessed through a YouTube link to a private channel.
Study NCT05658731 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: substructure informed planning
Description: Radiation Therapy with substructure informed planning determined by the PI.
Study NCT06041477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential PD-1 antibody
Description: PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR) (dosage and frequency according to instructions)
Study NCT05658731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Testing
Description: California Verbal Learning Test (CVLT) and other cognition assessments.
Study NCT05658731 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurocognitive Testing
Description: California Verbal Learning Test (CVLT) and other cognition assessments.
Study NCT05658731 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic resonance imaging (MRI) using whole brain diffusion tensor imaging (DTI) and resting state functional MRI (rsfMRI).
Study NCT05658731 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: Magnetic resonance imaging (MRI) using whole brain diffusion tensor imaging (DTI) and resting state functional MRI (rsfMRI).
Study NCT04973748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioned open-label placebo (COLP)
Description: Placebo oxycodone will be formulated to have the same physical appearance as liquid oxycodone and will be dispensed by the inpatient pharmacy and administered by the nursing staff. At all times that oxycodone or placebo medication is administered on post-operative day (POD) 1-5, the patient will undergo conditioning via exposure to a clove oil scent:~1. Conditioning (i.e. exposure to clove oil scent) with each dose of oxycodone medication on POD 1-5.~2. Scheduled placebo oxycodone medication paired with conditioning (i.e. exposure to clove oil scent) 3 times per day on POD 2-5.
Study NCT04973748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys about pain, opioid use and depression symptoms
Description: Surveys before surgery: Within 1 week prior to surgery, patients complete surveys about pain levels, opioid consumption, understanding of placebo effect and symptoms of depression.~Surveys after surgery: Through 6-months after surgery, patients complete surveys about pain levels, opioid consumption, side effects of opioids and symptoms of depression.
Study NCT04973748 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surveys about pain, opioid use and depression symptoms
Description: Surveys before surgery: Within 1 week prior to surgery, patients complete surveys about pain levels, opioid consumption, understanding of placebo effect and symptoms of depression.~Surveys after surgery: Through 6-months after surgery, patients complete surveys about pain levels, opioid consumption, side effects of opioids and symptoms of depression.
Study NCT05635760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Parent-implemented Social Communication Training
Description: The intervention will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
Study NCT05635760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-learning-based Parent-implemented Social Communication Training
Description: Self-learning families will learn the same materials without the guidance of a therapist.
Study NCT05564494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bankart Repair
Description: Patients Randomized to Bankart Repair Group
Study NCT05564494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomic Glenoid Reconstruction
Description: Patients Randomized to Anatomic Glenoid Reconstruction Group
Study NCT06150001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rocuronium-normal-saline mixture
Description: rocuronium will be pre-diluted with 2mL of normal saline. Researchers will inject the mixture into intravenous catheter.
Study NCT06150001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium-lidocaine mixture
Description: rocuronium will be pre-diluted with 2mL of 2%lidocaine. Researchers will inject the mixture into intravenous catheter.
Study NCT06150001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium-blood mixture
Description: Researchers will connect a syringe which contains 0.8mg/kg of rocuronium intravenous catheter, and then withdraw blood into the syringe. Finally inject the mixture into intravenous catheter.
Study NCT05552430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RelieveVRx
Description: Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.
Study NCT06567418 — intervention group
Intervention type: DRUG
Intervention: alirocumab 75mg/2week
Description: patients continually prescribed or stopped alirocumab treatment during the follow-up visit, which depend on physician's clinical decision and patient preference
Study NCT06567418 — intervention group
Intervention type: DRUG
Intervention: statin ± ezetimibe
Description: patients will be censored at initiation of alirocumab during the follow up visit
Study NCT05496634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedantary
Description: An informative presentation
Study NCT05496634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: Pilates exercise therapy
Study NCT05186727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family History education
Description: The education, developed in partnership with community partners, intends to assist women to collect family history of breast cancer and share it with their providers.
Study NCT05186727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Ambassador
Description: The support of a Patient Ambassador in addition to the education is also tested.
Study NCT05196802 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: mHeart.4u
Description: The mHeart.4U is a multiple-components intervention entailing the adoption and use of technological devices and self-management recommendations tailored to behavioural modifications (e.g. physical exercise and dietary patterns)
Study NCT05878600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kendall's exercise
Description: comparative effect of targeted cervical spine strengthening versus kendalls exercise will be analyzed